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BACKGROUND: The left-ventricular myocardial performance index Tei 
is an echocardiographic parameter that incorporates the information of 
systolic and diastolic time intervals. While the prognostic value of selected 
systolic and diastolic parameters is well established after transcatheter 
aortic valve replacement, the role of Tei has not been evaluated in this 
setting.
METHODS AND RESULTS: Between August 2007 and December 
2015, consecutive patients with symptomatic, severe aortic stenosis 
and transthoracic echocardiography pre- and post-transcatheter aortic 
valve replacement were considered eligible for this analysis. The primary 
end point was all-cause mortality at 1 year after transcatheter aortic 
valve replacement. Of 824 patients with echocardiographic images to 
calculate Tei, pre-Tei was normal (<0.45) in 639 and high (≥0.45) in 185, 
whereas post-Tei was normal in 602 and high in 120, respectively. After 
adjustment for confounding factors, high pre-Tei was associated with 
an increased risk of all-cause mortality at 30 days (adjusted hazard ratio 
[HRadj] 3.62; 95% CI, 1.89–6.91) and 1 year (HRadj 2.56; 95% CI, 1.78–
3.69). Similarly, post-Tei was associated with an increased risk of mortality 
between 30 days and 1-year follow-up (HRadj 6.70; 95% CI, 4.22–10.63). 
At multivariable analysis Tei emerged as an independent predictor of early 
(pre-Tei index per 0.1–HRadj 1.40; 95% CI, 1.23–1.60) and late mortality 
(post-Tei index per 0.1–HRadj 1.40; 95% CI, 1.31–1.50), respectively.
CONCLUSIONS: The left-ventricular myocardial performance index Tei is 
associated with impaired clinical outcomes during short- and longer-term 
follow-up after transcatheter aortic valve replacement.
VISUAL OVERVIEW: A visual overview is available for this article.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01368250.
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Among patients with severe aortic stenosis (AS), the development of heart failure symptoms cor-relates with disease severity and left ventricular 
(LV) hypertrophy and has been attributed to LV dias-
tolic and systolic dysfunction.1 While diastolic dysfunc-
tion (DD) is the result of chronic pressure overload and 
unfavorable myocardial remodeling, owing to impair-
ment of LV relaxation and changes in diastolic filling 
dynamics,2 systolic dysfunction may develop because of 
an excess in afterload and changes in LV contractility 
related to inadequate hypertrophy of the myocardium.3
Transcatheter aortic valve replacement (TAVR) is 
the treatment of choice for inoperable and patients at 
increased surgical risk, and has emerged as a less-inva-
sive therapeutic option for intermediate risk patients 
with symptomatic, severe AS. So far, only selected ech-
ocardiographic diastolic and systolic parameters have 
been evaluated after TAVR and their prognostic value 
is still subject to controversy.4–6 The myocardial perfor-
mance index Tei is recognized as echocardiographic pa-
rameter to determine overall cardiac performance and 
express global systolic and diastolic ventricular func-
tion.7 While the prognostic value of Tei has been studied 
in patients with congestive heart failure and dilated car-
diomyopathy,8,9 the diagnostic and prognostic role of 
Tei in patients with severe AS undergoing TAVR remains 
to be elucidated.
METHODS
Patient Population and Procedures
Between August 2007 and December 2015, consecutive 
patients with symptomatic, severe AS undergoing TAVR 
were entered into the Bern TAVR Registry, which is part of 
the SwissTAVI Registry, and were considered eligible for this 
analysis.10 Patients were excluded in case non-Confédération 
Européenne-marked device were used, and in the absence of 
adequate echocardiographic data to assess Tei index within 
3 months before TAVR or 1 month after TAVR. Furthermore, 
patients with persistent atrial fibrillation and a history of 
permanent pacemaker implantation without showing sinus 
rhythm at the time point of echocardiographic assessments 
were excluded. TAVR was performed according to local ex-
pertise and standard techniques using a default transfemoral 
strategy, as described previously.11
The registry was approved by the local ethics committee, 
was conducted in accordance with the Declaration of Helsinki, 
and all patients provided written informed consent to partici-
pate during prospective follow-up. The present work adheres 
to the AHA Journals’ implementation of the Transparency 
and Openness Promotion Guidelines. In accordance with this 
policy, the Bern TAVR publication committee decided not 
to make the data, methods used during the analyses, and 
materials used to conduct the research available to any other 
person. However, we would consider sharing our data for 
purposes of scientific collaboration on request.
Echocardiography and Data Collection
All subjects underwent transthoracic echocardiography 
within 3 months before TAVR and at hospital discharge after 
TAVR. Routine echocardiographic follow-up assessment was 
recommended to be performed at 30 days after TAVR. For 
the assessment of echocardiographic measures, we selected 
3 of 15 consecutive heart beats and used the average of each 
parameter. Images were recorded with a workstation allow-
ing for offline analysis (Syngo Dynamics Workplace, version 
9.5, Siemens Medical Solutions, Inc, PA). Before (pre-Tei) and 
after TAVR (post-Tei), the LV Tei index was calculated using 
the following equation: Tei index=(ICT+IRT)/ET, where ICT 
denotes isovolumic contraction time, IRT isovolumic relaxa-
tion time, and ET refers to the ejection time (Figure I  in the 
Data Supplement). The mitral inflow velocity pattern and the 
LV outflow velocity pattern were recorded from the apical 
4-chamber view, and the apical long-axis view using pulsed 
wave Doppler, respectively. The predefined cutoff for normal 
Tei was <0.45, as previously reported.12 The echocardiographic 
evaluation was independently performed by board-certified 
cardiologists and experienced echocardiographers who were 
blinded to patient outcomes.
Clinical Follow-Up and End Point 
Assessment
Clinical follow-up was standardized and performed at 30 days 
(early) and 1-year (longer-term) follow-up after TAVR. All ad-
verse events were systematically collected and independently 
adjudicated according to the updated definitions of the Valve 
Academic Research Consortium-2. The primary end point was 
all-cause mortality within 1 year after TAVR.
Statistical Analysis
Continuous data are reported as means with SD (±SD, with 
P from t tests), and categorical variables are reported as 
WHAT IS KNOWN
• The left-ventricular myocardial performance index 
Tei is an echocardiographic parameter that incor-
porates the information of systolic and diastolic 
time intervals.
• While the prognostic value of selected systolic and 
diastolic parameters is well established after trans-
catheter aortic valve replacement, the role of Tei 
has not been evaluated in this setting.
WHAT THE STUDY ADDS
• We found an independent association of Tei index 
with worse clinical outcomes at 30 days and up 
to 1-year follow-up after transcatheter aortic valve 
replacement.
• Pre-transcatheter aortic valve replacement Tei index 
emerged as independent predictor of all-cause 
mortality at 30 days follow-up, whereas post- trans-
catheter aortic valve replacement Tei index was 
strongly associated with all-cause death, cardiovas-
cular death, and major adverse cardiovascular and 
cerebrovascular events between 30 days and 1 year.
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number of patients (% of patients, with P from χ2 tests, or 
in case of 2-by-2 associations Fisher exact tests), comparing 
pre-Tei index high versus normal, and again comparing post-
Tei index high versus normal.
Events are reported as counts of first occurrence per 
(sub)-type of event within 30 days or 1 year of follow-up (% 
of from lifetable estimates), comparing high pre-Tei versus 
normal pre-Tei index using Cox’s regressions (ie, censoring 
patients at death or lost to follow-up). Reported are crude 
hazard ratios (HR with 95% CI) with P from Wald χ2 tests, or 
continuity correct risk ratios with P from Fisher exact tests in 
case of zero events. Reported are adjusted HR (HRadj; 95% 
CI), with the pre-Tei high compared with pre-Tei normal. 
Adjusted analyses conducted in case >10 events were avail-
able overall. Post-Tei index was assessed up to 1-month fol-
low-up, accordingly high post-Tei index event rates were 
compared with normal post-Tei index using events reported 
from 30 days to 1 year of follow-up (by setting a landmark 
at 30 days, which includes only patients still at risk for that 
particular event starting from 30 days onwards). Again, both 
crude and HRadj (95% CI) are reported.
Predictors of 30-day clinical outcomes were evaluated 
separately (univariable Cox’s regressions). Similarly, predictors 
of clinical outcomes between 30 days to 1 year after TAVR 
were evaluated separately (univariable Cox’s regressions). 
These potential predictors were retained in the multivariable 
model, if the univariable P value was <0.2. The final model 
shows all potential predictors with P<0.2 in the multivariable 
model. Stratified analyses of the following subgroups were 
performed: sex (women versus men), LV ejection fraction (EF; 
<40% versus ≥40%), and Society of thoracic surgeon score 
(>8 versus 4–8 versus <4); and additionally the P value for 
the interaction between these subgroups (eg, women versus 
men) and Tei index are reported (high versus normal—sepa-
rate tables for pre- and post-Tei index). Exploratory analyses 
of combinations of pre-Tei and post-Tei index on clinical end 
points were also conducted (Tables I through IX in the Data 
Supplement). All analyses were performed with Stata version 
14.2 (StataCorp, College Station, TX). Two-sided P<0.05 were 
considered statistically significant.
RESULTS
Study Population
Out of 1339 consecutive patients undergoing TAVR dur-
ing the study period, the evaluation of pre- and post-Tei 
index was performed in 824 patients (61.5%; normal 
pre-Tei; n=639, high pre-Tei; n=185), and 722 (53.9%) 
patients (normal post-Tei; n=602, high post-Tei; n=120), 
respectively (Figure II in the Data Supplement).
Baseline clinical characteristics of the study popula-
tion are described in Table 1. Patients with normal and 
high pre-Tei index were comparable for most of the 
baseline characteristics, except for female sex (54.3% 
versus 38.9%; P<0.001), New York Heart Association 
functional class III or IV (64.3% versus 75.7%; P=0.004), 
and LVEF (55.2±14.7% versus 51.5±14.9%; P=0.004). 
Similarly, baseline characteristics were comparable for 
patients with normal and high post-Tei. Significant 
differences were found for paroxysmal atrial fibrilla-
tion (25.6% versus 38.3%, P=0.005), previous per-
manent pacemaker implantation (7.3% versus 15.8%, 
P=0.004), New York Heart Association functional class 
III or IV (63.6% versus 83.3%, P<0.001), Society of tho-
racic surgeons score (5.69±3.94% versus 6.63±4.39%, 
P=0.02), LVEF (55.4±14.5% versus 51.4±15.1%, 
P=0.008), and deceleration time (236.0±88.6 msec 
versus 217.6±81.6 msec, P=0.04).
Procedural Characteristics
Table  2 provides the information on procedural char-
acteristics between patient groups, showing significant 
differences in access route, valve type selection, and 
aortic regurgitation post TAVR greater than or equal 
to moderate among pre-Tei patients, whereas length 
of hospital stay, access route, valve type selection, 
and valve in series were different comparing normal 
and high post-Tei patients. A total of 182 patients re-
ceived permanent pacemaker during the early peripro-
cedural period after TAVR. Among them, 45 patients 
(high pre-Tei; 15 patients, normal pre-Tei; 30 patients) 
were excluded from the measurement of post-Tei index 
because of permanent pacemaker rhythm. For the re-
maining 137 patients sufficient echocardiographic data 
were available to calculate Tei index (Figure II in the 
Data Supplement).
Clinical Outcomes According to Pre- and 
Post-Tei Index
Event rates with crude and HRadj for clinical end points 
are provided in Tables  3 and 4. The primary end point 
of all-cause mortality at 12 months was observed in 124 
(15.0%) patients (normal versus high Tei; 11.6% versus 
28.0%; HRadj. 2.56; 95% CI, 1.78–3.69; P<0.001) with 
pre-Tei index, and occurred in 75 (12.5%) patients (6.1% 
versus 38.8%; HRadj. 6.70; 95% CI, 4.22–10.6; P<0.001) 
with post-Tei index assessment (Figure 1A and 1B).
Among patients with pre-Tei assessment, secondary 
end points including cardiovascular death and major 
adverse cardiovascular and cerebrovascular events 
(MACCE) at 30 days were observed in 33 (4.0%; 
2.7% versus 8.8%; HRadj. 3.11; 95% CI, 1.55–6.22; 
P=0.001) and 55 patients (6.7%; 4.7% versus 13.6%; 
HRadj. 2.74; 95% CI, 1.60–4.71; P<0.001). After 1-year 
follow-up cardiovascular death and MACCE was 
observed in 82 (10.0%; 7.1% versus 21.6%; HRadj. 
3.09; 95% CI, 1.98–4.81; P<0.001) and 151 patients 
(18.3%; 14.2% versus 33.5%; HRadj. 2.54; 95% CI, 
1.83–3.53; P<0.001), respectively (Figure  1C and 
1E). Moreover, life-threatening bleeding at 30 days 
(HRadj. 2.14; 95% CI, 1.28–3.59) and disabling stroke 
at 1-year follow-up (HRadj. 3.00; 95% CI, 1.44–6.27) 
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were more frequently observed among patients with 
high pre-Tei index compared with patients and normal 
pre-Tei values (Table 3).
Among patients with post-Tei assessment, cardiovas-
cular death, and MACCE were observed in 42 (5.8%; 
3.5% versus 24.6%; HRadj. 6.34; 95% CI, 3.40–11.8; 
P<0.001) and 82 patients (11.4%; 7.5% versus 41.2%; 
HRadj. 6.35; 95% CI, 4.09–9.88; P<0.001) between 30 
days and 1 year (Figure 1D and 1F). Subgroup analy-
ses for pre- and post-Tei indices demonstrated a con-
sistent effect across all subgroups. (Figure 2; Figure III 
in the Data Supplement). During subgroup analyses, 
significant interaction was found between the effect of 
pre-Tei on all-cause death at 30 days and patients with 
Table 1. Baseline Clinical Characteristics
 
Pre-Tei Index Post-Tei Index
All Patients Normal High
P Value
All Patients Normal High
P ValueN=824 N=639 N=185 N=722 N=602 N=120
Age, y 82.2±6.2 82.3±6.2 81.8±6.4 0.30 82.2±6.1 82.2±6.1 82.0±6.1 0.69
Female sex, n (%) 419 (50.8) 347 (54.3) 72 (38.9) <0.001 368 (51.0) 316 (52.5) 52 (43.3) 0.07
Body mass index, kg/m2 26.3±5.2 26.5±5.2 25.8±5.2 0.08 26.3±5.2 26.5±5.2 25.8±4.9 0.19
Cardiac risk factors
  Diabetes mellitus, n (%) 218 (26.5) 172 (26.9) 46 (24.9) 0.64 183 (25.3) 149 (24.8) 34 (28.3) 0.42
  Hypercholesterolemia, n (%) 529 (64.2) 412 (64.5) 117 (63.2) 0.79 461 (63.9) 376 (62.5) 85 (70.8) 0.10
  Hypertension, n (%) 690 (83.7) 541 (84.7) 149 (80.5) 0.21 605 (83.8) 502 (83.4) 103 (85.8) 0.59
Past medical history
  Previous myocardial infarction, n (%) 130 (15.8) 93 (14.6) 37 (20.0) 0.09 107 (14.8) 86 (14.3) 21 (17.5) 0.40
  Previous PCI, n (%) 218 (26.5) 170 (26.6) 48 (25.9) 0.93 194 (26.9) 160 (26.6) 34 (28.3) 0.74
  Previous CABG, n (%) 98 (12.4) 75 (12.1) 23 (13.2) 0.70 90 (12.9) 76 (13.1) 14 (12.3) 1.00
  Previous stroke or TIA, n (%) 94 (11.4) 71 (11.1) 23 (12.4) 0.60 83 (11.5) 73 (12.1) 10 (8.3) 0.27
  Peripheral vascular disease, n (%) 129 (15.7) 93 (14.6) 36 (19.5) 0.11 111 (15.4) 87 (14.5) 24 (20.0) 0.13
  Chronic obstructive pulmonary 
disease, n(%)
100 (12.2) 76 (11.9) 24 (13.0) 0.70 88 (12.2) 68 (11.3) 20 (16.7) 0.13
  Renal failure (eGFR<60 mL/min per 
1.73 m2), n (%)
577 (70.0) 450 (70.4) 127 (68.6) 0.65 503 (69.7) 413 (68.6) 90 (75.0) 0.19
Baseline cardiac rhythm
  Paroxysmal AF,* n (%) 237 (28.8) 179 (28.0) 58 (31.4) 0.41 200 (27.7) 154 (25.6) 46 (38.3) 0.005
  Permanent pacemaker, n (%) 76 (9.2) 55 (8.6) 21 (11.4) 0.25 63 (8.7) 44 (7.3) 19 (15.8) 0.004
Symptoms
  NYHA classification III or IV, n (%) 551 (66.9) 411 (64.3) 140 (75.7) 0.004 483 (66.9) 383 (63.6) 100 (83.3) <0.001
  CCS III or IV Angina, n (%) 74 (9.0) 56 (8.8) 18 (9.7) 0.66 66 (9.1) 51 (8.5) 15 (12.5) 0.17
Risk assessment
  Logistic EuroSCORE, % 20.0±13.3 19.8±13.4 20.6±13.0 0.49 19.7±13.3 19.3±13.1 21.5±14.2 0.10
  STS score, % 5.90±3.97 5.90±4.12 5.90±3.42 1.00 5.84±4.03 5.69±3.94 6.63±4.39 0.02
Echocardiography
  LV ejection fraction, % 54.4±14.8 55.2±14.7 51.5±14.9 0.004 54.7±14.7 55.4±14.5 51.4±15.1 0.008
  Aortic valve area, cm2 0.67±0.25 0.66±0.25 0.68±0.25 0.30 0.67±0.25 0.66±0.25 0.71±0.26 0.11
  Mean gradient, mm Hg 42.2±17.7 42.5±17.6 41.3±18.2 0.45 42.3±17.9 42.6±17.6 40.5±19.4 0.25
  Deceleration time, ms 230.3±86.2 231.3±87.8 226.7±80.4 0.53 232.9±87.7 236.0±88.6 217.6±81.6 0.04
  Tei index 0.37±0.17 0.31±0.08 0.61±0.17 <0.001 0.37±0.16 0.34±0.12 0.54±0.24 <0.001
  LVET, ms 312.3±40.4 320.1±37.7 285.1±37.8 <0.001 312.3±40.0 316.4±37.5 292.2±46.1 <0.001
  IVCT, ms 32.8±48.9 17.3±32.3 86.9±57.8 <0.001 32.1±48.6 24.4±39.9 70.8±67.2 <0.001
  IVRT, ms 81.0±23.4 80.0±23.1 84.6±23.8 0.02 81.2±23.5 81.4±23.5 79.1±22.8 0.67
Values are mean±SD or counts (%). P value from χ2 tests (Fisher test in case of 2×2 table) or t test (for age and BMI). AF indicates atrial fibrillation; CABG, 
coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; eGFR, estimated glomerular filtration rate; IVCT, isovolumic contraction time; IVRT, isovolumic 
relaxation time; LV, left ventricle; LVET, left ventricular ejection time; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of 
Thoracic Surgeons; and TIA, transient ischemic attack.
*At the time point of echocardiographic assessments in sinus rhythm.
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moderate or severe AR after TAVR and between post-
Tei on all-cause death between 30 days and 1 year and 
reduced LVEF (<40%) after TAVR (Figure III in the Data 
Supplement).
Clinical Outcomes According to 
Categories of Pre- and Post-Tei Index
Patients were grouped according to the evolution of 
post-Tei index in relation to pre-Tei assessment. Out 
of 185 patients with high pre-Tei index, Tei changed 
to normal values after the intervention in 91 (49.2%) 
patients, whereas 50 (7.8%) patients with normal Tei 
at baseline had high Tei index after TAVR. Patients with 
high pre-Tei index and high post-Tei index (HH) were 
more often men, more often had paroxysmal atrial fi-
brillation, previous permanent pacemaker implantation, 
presented in New York Heart Association functional 
class III or IV, had higher surgical risk, lower LVEF, and 
lower deceleration time compared with patients with 
normal pre-Tei and normal post-Tei index (NN; Table I 
in the Data Supplement). Significant differences were 
found in terms of access route, type of valve selection, 
and length of hospital stay comparing HH patients with 
NN (Table II in the Data Supplement). Furthermore, 
there were higher rates of all-cause death, cardiovas-
cular death, and MACCE between 30 days and 1-year 
follow-up in patients with high post-Tei index (both 
NH and HH groups; Tables III and IV, Figure IV in the 
Data Supplement). The difference between pre- and 
post-Tei index and its effect on clinical outcomes was 
evaluated. Consistent results were observed according 
to Tei change for all-cause death, cardiovascular death, 
and MACCE and are presented in Table V in the Data 
Supplement.
Predictors for Adverse Clinical Outcomes
Independent predictors for death from any cause are 
displayed in Table 5. Multivariable analyses identified 
pre-Tei index (per 0.1–HRadj. 1.40; 95% CI, 1.23–1.60) 
as an independent predictor of all-cause mortality 
during short-term follow-up. Moreover, post-Tei 
index (per 0.1–HRadj. 1.40; 95% CI, 1.31–1.50); dia-
betes mellitus (HRadj. 2.78; 95% CI, 1.72–4.50); LVEF 
(HRadj. 0.98; 95% CI, 0.96–0.99), and lower body mass 
index (HRadj. 2.70; 95% CI, 1.30–5.60) emerged as in-
dependent predictors of all-cause death between 30 
Table 2. Procedural Characteristics
 
Pre-Tei Index Post-Tei Index
All Patients Normal High
P Value
All Patients Normal High
P ValueN=824 N=639 N=185 N=722 N=602 N=120
Procedural characteristics
  Procedure time, min 60 (46–81.8) 60 (47–80.3) 59 (45–84.3) 0.88 59 (46–82) 59 (46–80) 61 (48–88) 0.20
  Length of hospital stay, d 8 (6–10) 8 (6–10) 8 (6–11) 0.45 8 (6–10) 8 (6–10) 9 (7–12.3) 0.011
  General anesthesia, n (%) 232 (28.2) 175 (27.4) 57 (30.8) 0.40 186 (25.8) 153 (25.4) 33 (27.5) 0.65
Access route    0.04    0.004
  Femoral, n (%) 717 (87.0) 565 (88.4) 152 (82.2) 0.03 645 (89.3) 539 (89.5) 106 (88.3) 0.75
  Apical, n (%) 96 (11.7) 67 (10.5) 29 (15.7) 0.07 66 (9.1) 57 (9.5) 9 (7.5) 0.60
  Subclavian, n (%) 8 (1.0) 4 (0.6) 4 (2.2) 0.08 8 (1.1) 3 (0.5) 5 (4.2) 0.004
  Other, n (%) 3 (0.4) 3 (0.5) 0 (0.0) 1.00 3 (0.4) 3 (0.5) 0 (0.0) 1.00
Valve type    0.001    0.001
  Medtronic CoreValve, n (%) 264 (32.0) 194 (30.4) 70 (37.8) 0.06 239 (33.1) 182 (30.2) 57 (47.5) <0.001
  Edwards Sapien XT, n (%) 221 (26.8) 156 (24.4) 65 (35.1) 0.005 191 (26.5) 155 (25.7) 36 (30.0) 0.37
  BSC/Symetis ACURATE valve, 
n (%)
34 (4.1) 28 (4.4) 6 (3.2) 0.67 26 (3.6) 26 (4.3) 0 (0.0) 0.01
  Abbott/SJM Portico, n (%) 4 (0.5) 4 (0.6) 0 (0.0) 0.58 4 (0.6) 4 (0.7) 0 (0.0) 1.00
  Edwards Sapien 3, n (%) 190 (23.1) 165 (25.8) 25 (13.5) <0.001 166 (23.0) 147 (24.4) 19 (15.8) 0.04
  BSC Lotus, n (%) 56 (6.8) 47 (7.4) 9 (4.9) 0.32 45 (6.2) 41 (6.8) 4 (3.3) 0.21
  Medtronic Evolut R, n (%) 55 (6.7) 45 (7.0) 10 (5.4) 0.51 51 (7.1) 47 (7.8) 4 (3.3) 0.12
Procedural specifications
  Post-TAVR AR moderate or 
severe, n (%)
74 (9.0) 50 (7.8) 24 (13.0) 0.04 69 (9.6) 57 (9.5) 12 (10.0) 0.87
  Valve in valve, n (%) 16 (1.9) 14 (2.2) 2 (1.1) 0.55 15 (2.1) 9 (1.5) 6 (5.0) 0.03
Values are counts (%) or medians (25%–75% interquartile range). P Value from χ2 tests (Fisher test in case of 2×2 table) or t test (for procedure time and 
length of stay). AR indicates aortic regurgitation; and TAVR, transcatheter aortic valve replacement.
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days and 1 year after TAVR. Predictors for worsening 
and improving Tei index are presented in Table VI and 
VII in the Data Supplement.
Short- and Long-term clinical Outcomes accord-
ing to pre- and post-Tei index in patients exclusively 
in sinus rhythm without previous history of any atrial 
fibrillation is provided in Table VIII and IX in the Data 
Supplement.
DISCUSSION
The salient findings of our study investigating the as-
sociation of periprocedural Tei index and clinical out-
comes after TAVR can be summarized as follows:
1. One-quarter of patients undergoing TAVR for se-
vere AS were found to have impaired LV myocar-
dial performance according to the Tei index.
Table 3. Short- and Long-Term Clinical Outcomes According to Pre-Tei Index
 
Normal Pre-Tei 
Index Patients
High Pre-Tei 
Index Patients Crude Hazard Ratio Adjusted Hazard Ratio
N=639 N=185 HR (95% CI) P Value
Adjusted HR  
(95% CI)
Adjusted  
P Value
30-D follow-up
  All-cause death, n (%) 18 (2.8) 20 (10.9) 3.99 (2.11–7.54) <0.001 3.62 (1.89–6.91) <0.001
   Cardiovascular death, n (%) 17 (2.7) 16 (8.8) 3.37 (1.70–6.68) <0.001 3.11 (1.55–6.22) 0.001
  Myocardial infarction, n(%) 8 (1.3) 3 (1.6) 1.30 (0.34–4.90) 0.70 1.40 (0.37–5.36) 0.62
  Cerebrovascular events
   Disabling stroke, n (%) 14 (2.2) 9 (5.0) 2.25 (0.98–5.21) 0.06 2.28 (0.98–5.31) 0.06
  MACCE, n (%) 30 (4.7) 25 (13.6) 2.95 (1.73–5.01) <0.001 2.74 (1.60–4.71) <0.001
  Bleeding
   Life-threatening, n (%) 39 (6.1) 24 (13.1) 2.18 (1.31–3.62) 0.003 2.14 (1.28–3.59) 0.004
  Kidney injury
   Stage 3, n (%) 19 (3.0) 9 (4.9) 1.66 (0.75–3.66) 0.21 1.81 (0.81–4.03) 0.15
  Access site complications
   Major, n (%) 68 (10.7) 23 (12.5) 1.18 (0.73–1.89) 0.50 1.17 (0.73–1.88) 0.51
1-Y follow-up
  All-cause death, n (%) 73 (11.6) 51 (28.0) 2.71 (1.89–3.87) <0.001 2.56 (1.78–3.69) <0.001
   Cardiovascular death, n (%) 44 (7.1) 38 (21.6) 3.31 (2.14–5.11) <0.001 3.09 (1.98–4.81) <0.001
  Myocardial infarction, n (%) 13 (2.1) 6 (3.7) 1.73 (0.66–4.56) 0.27 1.75 (0.66–4.66) 0.26
  Cerebrovascular events
   Disabling stroke, n (%) 16 (2.6) 13 (7.7) 2.95 (1.42–6.15) 0.004 3.00 (1.44–6.27) 0.003
  MACCE, n (%) 90 (14.2) 61 (33.5) 2.65 (1.92–3.67) <0.001 2.54 (1.83–3.53) <0.001
No. of events (% from lifetable estimate). Hazard ratios (HR; 95% CI) from Cox regressions for time-to-event data. In case of >10 event also reported: 
Adjusted (HRs; 95% CI) from Cox regressions adjusting for diabetes mellitus, peripheral vascular disease, paroxysmal atrial fibrillation, BMI ≤20, logistic 
EuroSCORE ≥40%, concomitant PCI. Fisher exact test and continuity correct Risk ratios reported in case of zero events in 1 group. MACCE indicates major 
adverse cardiovascular and cerebrovascular events (composite of all-cause death, stroke, and myocardial infarction).
Table 4. Post 30-Day Clinical Outcomes According to Post-Tei Index
 
Normal Post-Tei 
Index Patients
High Post-Tei 
Index Patients Crude Hazard Ratio Adjusted Hazard Ratio
n=602* n=120* HR (95% CI) P Value HR (95% CI) P Value
30-d follow-up to 1 y*
  All-cause death, n (%) 36 (6.1) 39 (38.8) 7.60 (4.83–11.96) <0.001 6.70 (4.22–10.63) <0.001
   Cardiovascular death, n (%) 20 (3.5) 22 (24.6) 7.82 (4.26–14.34) <0.001 6.34 (3.40–11.80) <0.001
  Myocardial infarction, n (%) 5 (0.9) 1 (1.2) 1.55 (0.18–13.25) 0.69 1.88 (0.21–16.76) 0.57
  Cerebrovascular events
   Disabling stroke, n(%) 2(0.4) 3(4.0) 12.08(2.01–72.44) 0.006 12.76(2.12–76.92) 0.005
  MACCE, n(%) 43(7.5) 39(41.2) 6.81(4.41–10.51) <0.001 6.35(4.09–9.88) <0.001
No. of events (% from lifetable estimate). Hazard ratios (HR; 95% CI) from Cox regressions for time-to-event data. In case of >10 event also reported: Adjusted 
HRs (95% CI) from Cox regressions adjusting for diabetes mellitus, peripheral vascular disease, paroxysmal atrial fibrillation, BMI ≤20, logistic EuroSCORE ≥40%, 
concomitant PCI. Fisher exact test and continuity correct Risk ratios reported in case of zero events in 1 group. MACCE indicates major adverse cardiovascular and 
cerebrovascular events (composite of all-cause death, stroke, and myocardial infarction); and PCI, percutaneous coronary intervention.
*Landmark at 30 days, that is, excludes patients no longer at risk for the specified event at day 30.
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2. Pre-Tei index was associated with worse clinical 
outcomes after TAVR and emerged as independent 
predictor of all-cause mortality at 30 days.
3. Moreover, post-Tei index was strongly associated 
with all-cause death, cardiovascular death, and 
MACCE between 30 days and 1 year.
The LV Tei index is an established echocardiographic 
parameter of advanced heart disease and a well-
known predictor of worse clinical outcomes among 
patients with different types of cardiomyopathy, in-
cluding ischemic, dilated, or hypertrophic heart di-
sease.8,9 Furthermore, LV Tei is effective in the early 
detection of subclinical ventricular dysfunction in 
patients with insulin resistance13 and is used as early 
reference marker for hypertensive cardiomyopathy 
in children with essential hypertension.14 However, 
it lacks precision and reproducibility in patients with 
atrial fibrillation, pacemaker rhythm, frequent ven-
tricular ectopic stimuli, and disturbances of intraven-
tricular or atrioventricular conduction.15 Our analysis 
suggests that LV Tei index also provides important 
prognostic information for patients with sympto-
matic, severe AS undergoing TAVR. While an elevated 
Tei index at baseline was associated with a 3.5- to 
2.5-fold increased risk of mortality after 30 days and 
12 months after TAVR, an increased Tei index after 
TAVR was found to be linked to a 6-fold increased 
risk of mortality and MACCE up to 1-year after TAVR. 
The adverse effect of high Tei index was observed irre-
spective of sex, Society of thoracic surgeons risk, and 
LVEF (Figure 2), which are well-established predictors 
for clinical outcomes after TAVR.
Figure 1. Kaplan-Meier analysis of end points after transcatheter aortic valve replacement (TAVR).  
Landmark analysis at 30 d for cumulative incidence of all-cause death (A), cardiovascular death (C), and major adverse cardiovascular and cerebrovascular events 
(MACCE; E) according to pre-Tei index. Cumulative incidence of all-cause death (B), cardiovascular death (D), and MACCE (F) between 30 d and 1 y according to 
post-Tei index. Blue line = normal Tei index; Red line = high Tei index.
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LV Tei index is considered a global myocardial perfor-
mance index as it incorporates time intervals of systolic 
and diastolic ventricular function from Doppler echo-
cardiographic images. It is well established, that systolic 
LV dysfunction is associated with increased opera-
tive mortality after surgical aortic valve replacement,16 
and considered one of the main reasons to circum-
vent surgery in the past. While, in the PARTNER I trial 
(Placement of Aortic Transcatheter Valves; cohort B+A), 
patients with classical low-flow, low-gradient severe AS 
had worse clinical outcomes after 2 years compared 
with normal flow patients,17 no significant differences 
in outcomes were observed between surgical aortic 
valve replacement and TAVR patients. Both treatment 
options were able to restore LVEF to a similar extent 
and provided comparable levels of LVEF improvement 
in the absence of right ventricle pacing or new onset 
left bundle branch block during follow-up. In contrast 
to the PARTNER data, a meta-analysis encompassing 
>7600 patients from 16 studies was able to show that 
reduced LVEF was associated with increased mortality 
at 1-year follow-up. This adverse effect was consist-
ently observed in patients with LVEF <50% (HR 1.52; 
95% CI, 1.31–1.76) and LVEF <30% (HR 1.60; 95% CI, 
1.19–2.16).18
Furthermore, among patients with symptomatic, se-
vere AS, chronic pressure overload, and unfavorable my-
ocardial remodeling because of cardiac hypertrophy is 
linked to impairment of LV relaxation and changes in 
diastolic filling.2 After conventional surgical aortic valve 
replacement, moderate-to-severe DD has been associ-
ated with relevant difficulties in perioperative weaning 
of cardiopulmonary bypass and was associated with 
worse clinical outcomes during longer-term follow-up 
up to 2 years after surgery.19,20 Studies on the prognostic 
role of DD among patients undergoing TAVR are limited 
in number and patient size.4,21 Most recently, data from 
a single center registry suggest that baseline DD was 
associated with mortality at 12 months (HR 1.163; 95% 
CI, 1.049–1.277; P=0.005) and the end point death/car-
diovascular hospitalization (HR 1.174; 95% CI, 1.032–
1.318; P=0.018) after TAVR. However, DD post-TAVR or 
changes in DD grade from baseline to follow-up did not 
emerge as predictor for worse clinical outcomes in 90 
TAVR patients.4 Conte et al21 investigated the prognostic 
role of LV stiffness as expression of DD and was able to 
show that increased myocardial stiffness was associated 
with mortality at 12 months. Patients with a combina-
tion of high LV stiffness and moderate-to-severe para-
valvular AR after TAVR were at particular risk for worse 
clinical outcomes, according to this study.
In our study, the LV Tei index was associated with 
worse clinical outcomes during the first year after TAVR, 
irrespective whether baseline or post-TAVR measures 
were used in multivariate analysis. By including sys-
tolic and diastolic time intervals to calculate Tei, this 
index might be considered a marker of global cardiac 
function and a reference parameter of advanced heart 
Figure 2. All-cause death after TAVR, stratified by sex, LVEF, and STS score.  
All-cause death at 30 days based on pre-Tei index and all-cause death between 30 d and 1 y based on post-Tei index. Black squares represent hazard ratios (HR); 
horizontal black lines illustrate CI. An HR>1 (right side) is in favor of high pre-/post-Tei index patients, whereas an HR<1 (left side) is in favor of normal pre-/post-Tei 
index patients. Pre-Tei index up to 30 d all-cause death, post-Tei using a landmark at 30 d and all-cause death from 30 d to 1 y of follow-up. *Interaction P testing 
for an effect modification of the subgroups on the difference in all-cause death between high and normal Tei index group. LVEF indicates left ventricular ejection 
fraction; STS; Society of Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement.
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disease in patients with symptomatic, severe AS under-
going TAVR. As Tei predicts worse clinical outcomes 
after TAVR irrespective of LVEF, future studies will show 
whether risk assessment using the standard surgical risk 
score algorithms may benefit from replacing systolic EF 
with LV Tei index.
Study Limitations
The findings of our study have to be interpreted in 
light of several limitations. First, the study population 
was based on the experience of a single, tertiary care 
center and the results might not be extrapolated to 
other centers with differences in patient selection and 
procedural experience. Second, we assessed pre- and 
post-Tei index in all patients irrespective of concomitant 
valvular heart disease (significant aortic/mitral regur-
gitation), coronary artery disease, or after pacemaker 
implantation, which might have a differential effect on 
Tei. Third, patients with permanent atrial fibrillation or 
paced cardiac rhythm at the time point of echocardi-
ographic assessment had to be excluded because of 
the inability to provide a precise and reliable calculation 
of Tei in the absence of an A-wave. Finally, we report 
results from a relatively modest number of patients and 
not all consecutive patients had sufficient echocardio-
graphic imaging quality to evaluate Tei pre- and post-
TAVR. However, the current TAVR patient population 
provides the largest echo dataset evaluating the effect 
of Tei in the present literature, is used from a prospec-
tive registry, which adheres to high standards of data 
quality with rigorous data collection, standardized fol-
low-up, and independent event adjudication at regular 
time intervals.
Conclusions
The LV myocardial performance index Tei is associated 
with impaired clinical outcomes after TAVR. Future studies 
will need to confirm the role of Tei as parameter for risk 
stratification in a patient population undergoing TAVR.
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Table 5. Predictive Factors for All-Cause Death
Variables
Univariate Analysis Multivariable Analysis Final Model
HR (95% CI) P Value
Adjusted HR  
(95% CI) P Value
Adjusted HR  
(95% CI) P Value
All-cause death at 30 d
Pre-Tei index (per 0.1) 1.42 (1.24–1.61) <0.001 1.38 (1.21–1.58) <0.001 1.40 (1.23–1.60) <0.001
Logistic EuroSCORE ≥40% 3.40 (1.60–7.20) 0.001 2.71 (1.15–6.37) 0.022 2.89 (1.36–6.14) 0.006
Previous stroke or TIA 1.82 (0.80–4.13) 0.155 1.61 (0.70–3.68) 0.26  0.30*
BMI ≤20 kg/m2 2.29 (0.95–5.48) 0.064 1.60 (0.64–4.03) 0.32  0.31*
LVEF, % 0.98 (0.96–1.00) 0.104 1.00 (0.98–1.02) 0.97  0.90*
All-cause death† 30 d to 1 y
Post-Tei index (per 0.1) 1.40 (1.31–1.48) <0.001 1.40 (1.30–1.50) <0.001 1.40 (1.31–1.50) <0.001
Diabetes mellitus 2.46 (1.59–3.80) <0.001 2.81 (1.73–4.59) <0.001 2.78 (1.72–4.50) <0.001
LVEF, % 0.97 (0.95–0.98) <0.001 0.98 (0.96–1.00) 0.012 0.98 (0.96–0.99) 0.007
BMI ≤20 kg/m2 1.87 (0.99–3.52) 0.054 2.78 (1.32–5.87) 0.007 2.70 (1.30–5.60) 0.008
Logistic. EuroSCORE ≥40% 3.40 (2.02–5.74) <0.001 1.51 (0.76–2.99) 0.24 1.66 (0.85–3.24) 0.14
Peripheral vascular disease 1.84 (1.11–3.05) 0.017 1.51 (0.84–2.70) 0.17  0.25*
Paroxysmal atrial fibrillation 1.68 (1.08–2.61) 0.023 1.36 (0.82–2.27) 0.24  0.37*
NYHA III or IV 1.81 (1.07–3.05) 0.026 0.86 (0.48–1.54) 0.61  0.64*
Creatinine >200μmol/L 1.61 (0.59–4.40) 0.35     
Women 0.89 (0.57–1.37) 0.59     
COPD 1.46 (0.81–2.64) 0.21     
Concomitant PCI 1.25 (0.69–2.27) 0.45     
Previous stroke or TIA 1.38 (0.75–2.55) 0.30     
Multivariable model includes variables with P<0.20 in the univariate analysis. Final Model after stepwise exclusion P<0.20, BMI indicates 
body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; and TIA, transient ischemic attack.
*P value of excluded variables if included into Final model.
†With landmark at 30 days.
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